公司資料
Nautilus Biotechnology 股價、新聞與催化劑
- 股票代碼:
- NAUT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.95 USD (+5.79%)
收盤價
最後更新: 2026年8月21日
341M USD
市值
股價為何變動
As of Aug 21, 2026, NAUT closed up 5.79% at $0.9545. No new same-company headline was identified in the current news window.
公司概覽
Single-Molecule Proteomics Platform
Nautilus Biotechnology is a development-stage life sciences company building a single-molecule proteomics platform intended to make comprehensive protein analysis more accessible. The platform is designed to quantify proteins and their proteoforms at scale, supporting research in disease biology, diagnostics, and drug development.
Voyager Instrument Platform
The Nautilus Voyager Platform is the company’s planned commercial instrument system. It is being designed to bring highly multiplexed single-molecule protein analysis into research and drug-development workflows.
Assay-Led Early Access
Before broad instrument availability, Nautilus is engaging customers through its Iterative Mapping Early Access service. The Tau Proteoforms Assay is the first available application, with AKT1 selected as the first oncology-focused proteoform assay.
Instrument and Consumables Model
Nautilus plans to progress from early-access services to a commercial model combining instruments, consumable kits, and targeted proteoform assays. This approach is intended to create recurring demand as the installed instrument base and application menu expand.
未來催化劑
- The AKT1 Proteoforms Assay is expected to enter Iterative Mapping Early Access by the end of 2026.
- Voyager Platform preorders are expected to open in early 2027, with initial instrument shipments planned for mid-2027.
- Consumable kits for the Tau, AKT1, and a second oncology proteoform assay are expected to become generally available in mid-2027, followed by a third oncology assay and additional kits by year-end 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。